(Q40821601)
Statements
A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis (English)
M A Menter
M Raman
D Disch
D E Schlichting
C Gaich
W Macias
X Zhang